Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal. Browse Full Report With TOC @ http://www.researchmoz.us/biosimilars-regulatory-framework-and-pipeline-analysis-report.html
http://www.researchmoz.us/biosimilars-regulatory-framework-and-pipeline-analysis-report.html
No comments:
Post a Comment